Literature DB >> 16541248

In rats chronically treated with clozapine, tyrosine depletion attenuates the clozapine-induced in vivo increase in prefrontal cortex dopamine and norepinephrine levels.

George E Jaskiw1, Bobbi Kirkbride, Rodolfo Bongiovanni.   

Abstract

We previously reported that depletion of brain tyrosine attenuated the acute clozapine (CLZ)-induced increase in medial prefrontal cortex (MPFC) dopamine (DA) levels. This effect was now examined after chronic CLZ treatment. Male rats received CLZ (10 mg kg(-1) day(-1)) in drinking water for 21 days. On day 18, a cannula was stereotaxically implanted over the MPFC. A microdialysis probe was inserted on day 20. On day 21 after a stable baseline was reached, rats received an acute injection of vehicle (VEH) or a tyrosine- and phenylalanine-free mixture of neutral amino acid [NAA(-)] (total 1 g kg(-1), i.p., two injections, 1 h apart) followed by CLZ (10 mg kg(-1), i.p.) or VEH. Basal tyrosine or norepinephrine (NE) levels were not different between the groups, but basal DA was higher in the group treated chronically with CLZ (p<0.05). Acute CLZ (10 mg kg(-1), i.p.) increased MPFC DA and NE levels to 370% and 510% of baseline, respectively, and similarly in rats chronically pretreated with CLZ or VEH. NAA(-) did not affect basal MPFC DA or NE levels but significantly attenuated acute CLZ-induced DA (220% of baseline) and NE (330% of baseline) levels (p<0.01) in rats pretreated chronically with CLZ or with VEH. These data demonstrate that even after chronic CLZ administration, the acute CLZ-induced increases in MPFC DA and NE levels depend on the availability of brain tyrosine. Judicious manipulation of brain tyrosine levels may provide a useful probe as well as a mechanism for enhancing psychotropic drug actions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541248     DOI: 10.1007/s00213-005-0283-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  58 in total

Review 1.  System L: heteromeric exchangers of large, neutral amino acids involved in directional transport.

Authors:  François Verrey
Journal:  Pflugers Arch       Date:  2002-11-21       Impact factor: 3.657

2.  Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-3',5'-monophosphate content in the rat caudate nucleus induced by the acute administration of an aminoacid mixture lacking tyrosine and phenylalanine.

Authors:  G Biggio; M L Porceddu; G L Gessa
Journal:  J Neurochem       Date:  1976-06       Impact factor: 5.372

3.  Tyrosine availability and dopamine synthesis in the striatum: studies with gamma-butyrolactone.

Authors:  A Sved; J Fernstrom
Journal:  Life Sci       Date:  1981-08-17       Impact factor: 5.037

4.  Response to stress of mesocortico-frontal dopaminergic neurones in rats after long-term isolation.

Authors:  G Blanc; D Hervé; H Simon; A Lisoprawski; J Glowinski; J P Tassin
Journal:  Nature       Date:  1980-03-20       Impact factor: 49.962

5.  Effects of a branched-chain amino acid drink in mania.

Authors:  A Scarna; H J Gijsman; S F B McTavish; C J Harmer; P J Cowen; G M Goodwin
Journal:  Br J Psychiatry       Date:  2003-03       Impact factor: 9.319

6.  In vivo tyrosine hydroxylation in the diabetic rat retina: effect of tyrosine administration.

Authors:  M H Fernstrom; E A Volk; J D Fernstrom
Journal:  Brain Res       Date:  1984-04-23       Impact factor: 3.252

7.  In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: II. Studies using potassium and tyramine.

Authors:  I S Fairbrother; G W Arbuthnott; J S Kelly; S P Butcher
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

8.  Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.

Authors:  B H Westerink; P de Boer; J B de Vries; C G Kruse; S K Long
Journal:  Eur J Pharmacol       Date:  1998-11-13       Impact factor: 4.432

9.  The transport of tyrosine into the human brain as determined with L-[1-11C]tyrosine and PET.

Authors:  F A Wiesel; G Blomqvist; C Halldin; I Sjögren; L Bjerkenstedt; N Venizelos; L Hagenfeldt
Journal:  J Nucl Med       Date:  1991-11       Impact factor: 10.057

10.  Dopamine release in rat striatum: physiological coupling to tyrosine supply.

Authors:  M J During; I N Acworth; R J Wurtman
Journal:  J Neurochem       Date:  1989-05       Impact factor: 5.372

View more
  6 in total

1.  A heuristic model for working memory deficit in schizophrenia.

Authors:  Zhen Qi; Gina P Yu; Felix Tretter; Oliver Pogarell; Anthony A Grace; Eberhard O Voit
Journal:  Biochim Biophys Acta       Date:  2016-05-10

Review 2.  Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.

Authors:  Claire Rampon; Bruno P Guiard; Basile Coutens; Antoine Yrondi
Journal:  Psychopharmacology (Berl)       Date:  2022-08-10       Impact factor: 4.415

3.  Presynaptic regulation of extracellular dopamine levels in the medial prefrontal cortex and striatum during tyrosine depletion.

Authors:  Zachary Brodnik; Manda Double; George E Jaskiw
Journal:  Psychopharmacology (Berl)       Date:  2013-02-01       Impact factor: 4.530

4.  Acute phenylalanine/tyrosine depletion of phasic dopamine in the rat brain.

Authors:  Tatiana A Shnitko; Sarah C Taylor; Sierra J Stringfield; Shannon L Zandy; Roberto U Cofresí; James M Doherty; William B Lynch; Charlotte A Boettiger; Rueben A Gonzales; Donita L Robinson
Journal:  Psychopharmacology (Berl)       Date:  2016-03-05       Impact factor: 4.530

5.  L-Tyrosine availability affects basal and stimulated catecholamine indices in prefrontal cortex and striatum of the rat.

Authors:  Zachary D Brodnik; Manda Double; Rodrigo A España; George E Jaskiw
Journal:  Neuropharmacology       Date:  2017-05-29       Impact factor: 5.250

6.  A Preclinical Study of Casein Glycomacropeptide as a Dietary Intervention for Acute Mania.

Authors:  Nico Liebenberg; Erik Jensen; Erik Roj Larsen; Birgitte Saima Kousholt; Vitor Silva Pereira; Christina Weide Fischer; Gregers Wegener
Journal:  Int J Neuropsychopharmacol       Date:  2018-05-01       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.